Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis

References

• Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–955
   PubMed Web of Science ®Google Scholar
• McQualter JL, Bernard CC. Multiple sclerosis: A battle between destruction and repair. J Neurochem 2006; 100: 295–306
   PubMed Web of Science ®Google Scholar
• Brass SD, Weiner HL, Hafler DA. Multiple sclerosis. The autoimmune diseases4th edn., NR Rose, IR Mackay. Elsevier Academic Press, San Diego 2006; 615–632
   Google Scholar
• Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006; 354: 965–967, [see comment][comment]
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol Res 2005; 32: 85–97
   PubMed Web of Science ®Google Scholar
• Stark JL, Cross AH. Differential expression of suppressors of cytokine signaling-1 and -3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. Int Immunol 2006; 18: 347–353
   PubMed Web of Science ®Google Scholar
• von Budingen HC, Tanuma N, Villoslada P, Ouallet JC, Hauser SL, Genain CP. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001; 21: 155–170
   PubMed Web of Science ®Google Scholar
• Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG, Bernard CC, Rossjohn J. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci USA 2003; 100: 11059–11064
   PubMed Web of Science ®Google Scholar
• Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L, Dimitri D, Roussel G, Dierich A, Amor S, Dautigny A, Liblau R, Pham-Dinh D. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 2003; 112: 544–553
   PubMed Web of Science ®Google Scholar
• Ben-Nun A, Kerlero de Rosbo N, Kaushansky N, Eisenstein M, Cohen L, Kaye JF, Mendel I. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): Prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur J Immunol 2006; 36: 478–493
   PubMed Web of Science ®Google Scholar
• Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med 1997; 75: 77–88
   PubMed Web of Science ®Google Scholar
• Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001; 36: 220–234
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Bernard CC, Oksenberg JR. Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J Immunol 2005; 174: 7412–7422
   PubMed Web of Science ®Google Scholar
• Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60: 12–21, [comment]
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997; 337: 1604–1611
   PubMed Web of Science ®Google Scholar
• Karlik SJ, Stavraky RT, Hall ED. Comparison of tirilazad mesylate (U-74006F) and methylprednisolone sodium succinate treatments in experimental allergic encephalomyelitis in the guinea pig. Mult Scler 1996; 11: 228–235
   Google Scholar
• Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, Bahr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993–7000
   PubMed Web of Science ®Google Scholar
• Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431–1441
   PubMed Web of Science ®Google Scholar
• Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005; 11: 425–432
   PubMed Web of Science ®Google Scholar
• Biondo M, Field J, Toh BH, Alderuccio F. Prednisolone promotes remission and gastric mucosal regeneration in field experimental autoimmune gastritis. J Pathol 2006; 209: 384–391
   PubMed Web of Science ®Google Scholar
• Jeffries GH. Recovery of gastric mucosa structure and function in pernicious anemia during prednisolone therapy. Gastroenterology 1965; 48: 371–378
   PubMed Web of Science ®Google Scholar
• Jeffries GH, Todd JE, Sleisenger MH. The effect of prednisolone on gastric mucosal histology, gastric secretion, and vitamin B 12 absorption in patients with pernicious anemia. J Clin Invest 1966; 45: 803–812
   PubMed Web of Science ®Google Scholar
• Wall AJ, Whittingham S, Mackay IR, Ungar B. Prednisolone and gastric atrophy. Clin Exp Immunol 1968; 3: 359–366
   PubMedGoogle Scholar
• Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA, Murray BM, Barres B, Tessier-Lavigne M, Bernard CC. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004; 7: 736–744
   PubMed Web of Science ®Google Scholar
• Trune DR, Kempton JB. Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas (lpr) autoimmune mice. Hear Res 2001; 155: 9–20
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Quddus J. Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. J Neuroimmunol 1986; 13: 159–174
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The optic neuritis study group. N Engl J Med 1993; 329: 1764–1769
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, Fera F, Gambardella A, Zappia M, Pardatscher K, Quattrone A. Randomized trial comparing two different high doses of methylprednisolone in MS: A clinical and MRI study. Neurology 1998; 50: 1833–1836
   PubMed Web of Science ®Google Scholar
• Alderuccio F, Toh BH. Induction of tolerance to self-antigens using genetically modified bone marrow cells. Expert Opin Biol Ther 2004; 4: 1007–1014
   PubMed Web of Science ®Google Scholar
• Siatskas C, Chan J, Field J, Murphy K, Nasa Z, Toh BH, Alderuccio F. Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr Gene Ther 2006; 6: 45–58
   PubMed Web of Science ®Google Scholar
• Murphy K, Biondo M, Toh BH, Alderuccio F. Tolerance established in autoimmune disease by mating or bone marrow transplantation that target autoantigen to thymus. Int Immunol 2003; 15: 1–9
   PubMed Web of Science ®Google Scholar
• Fox EJ. Immunopathology of multiple sclerosis. Neurology 2004; 63: S3–S7
   PubMedGoogle Scholar
• Hohlfeld R. Myelin failure in multiple sclerosis: Breaking the spell of Notch. Nat Med 2002; 8: 1075–1076, [comment]
   PubMed Web of Science ®Google Scholar
• Anderson MS, Bluestone JA. The NOD mouse: A model of immune dysregulation. Annu Rev Immunol 2005; 23: 447–485
   PubMed Web of Science ®Google Scholar
• Zorina TD, Subbotin VM, Bertera S, Alexander AM, Haluszczak C, Gambrell B, Bottino R, Styche AJ, Trucco M. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 2003; 21: 377–388
   PubMed Web of Science ®Google Scholar
• Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 2005; 48: 9–12
   PubMed Web of Science ®Google Scholar
• Stangel M, Hartung HP. Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol 2002; 68: 361–376
   PubMed Web of Science ®Google Scholar
• Pavelko KD, van Engelen BG, Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J Neurosci 1998; 18: 2498–2505
   PubMed Web of Science ®Google Scholar